Hoth Therapeutics (NASDAQ:HOTH) spotted trading -65.27% off 52-week high price. On the other end, the stock has been noted 21.39% away from the low price over the last 52-weeks. The stock changed -15.78% to recent value of $3.15. The stock transacted 812933 shares during most recent day however it has an average volume of 188.62K shares. The company has 10.80M of outstanding shares and 4.46M shares were floated in the market.
On March 24, 2020, Hoth Therapeutics (NASDAQ:HOTH) a biopharmaceutical company, announced the pricing of its previously notified best efforts underwritten public offering of 1,449,275 shares of its common stock at a price to the public of $3.45 per share. Hoth expects to receive aggregate gross proceeds of approximately $5 million from the offering, before deducting the underwriting discount and estimated offering expenses. The offering is expected to close on or about March 26, 2020, subject to customary closing conditions.
Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering. Roth Capital Partners is acting as a financial advisor to the Company.
Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent the COVID-19 virus, working capital, sales and marketing activities, and general and administrative matters.
Its earnings per share (EPS) expected to touch remained -69.50% for this year.
According to the most recent quarter its current ratio was 6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -16.32% from the mean of 20 days, -28.26% from mean of 50 days SMA and performed -35.85% from mean of 200 days price. Company’s performance for the week was 12.50%, -27.59% for month and YTD performance remained -49.11%.